31-45 of 937
Protecting Heart Health in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerProtecting Heart Health in Metastatic Breast Cancer
Ryan Quigley
Gregory Vidal, MD, PhD
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart MattersSupporting Patients With ATTR-CM: Preserving Function and Quality of Life
Joban Vaishnav, MD
Counseling Patients on Disease Progression in ATTR-CM
Heart MattersCounseling Patients on Disease Progression in ATTR-CM
Joban Vaishnav, MD
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart MattersRethinking Thromboembolic Risk in ATTR-CM Care
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart MattersSilencers and Stabilizers in ATTR-CM: Challenging Assumptions
Trends and Disparities in COPD with Secondary Pulmonary Hypertension
Clinician's RoundtableTrends and Disparities in COPD with Secondary Pulmonary Hypertension
Nasibul Alam, MD
- advertisement
Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
Clinician's RoundtableReframing Palliative Care in PAH: Early Integration to Improve Outcomes
Targeting Macrophages in Pulmonary Arterial Hypertension
Clinician's RoundtableTargeting Macrophages in Pulmonary Arterial Hypertension
Fatty Acid Profiles May Be Linked to PAH Risk
AudioAbstractsFatty Acid Profiles May Be Linked to PAH Risk
Ryan Quigley
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- advertisement
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart MattersHeart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Juan Badimon, PhD, FAHA
Frederick Ruberg, MD
